KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells

The MET receptor tyrosine kinase is often deregulated in human cancers and several MET inhibitors are evaluated in clinical trials. Similarly to EGFR, MET signals through the RAS‐RAF‐ERK/MAPK pathway which plays key roles in cell proliferation and survival. Mutations of genes encoding for RAS protei...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Leiser, Dominic, Medová, Michaela, Mikami, Kei, Nisa, Lluís, Stroka, Deborah, Blaukat, Andree, Bladt, Friedhelm, Aebersold, Daniel M., Zimmer, Yitzhak
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528816/
https://ncbi.nlm.nih.gov/pubmed/25933688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.04.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados